Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 740.

https://doi.org/10.1182/blood.V130.Suppl_1.740.740

Published: 2017

Journal Articles

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

Nasha Elavia, MD MBBS, Andrew McManus, Steven L Highfill, PhD, Jiaqiang Ren, MD PhD, Nirali N Shah, MD, Terry J. Fry, MD, Jennifer Brudno, MD, James N. Kochenderfer, MD, David Stroncek, MD, Sandhya R. Panch, MDMPH

Blood (2017) 130 (Supplement 1): 4475.

https://doi.org/10.1182/blood.V130.Suppl_1.4475.4475

Published: 2017

Journal Articles

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

Norris Lam, BS, Leah Alabanza, PhD, Nathan Trinklein, PhD, Ben Buelow, MD PhD, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 504.

https://doi.org/10.1182/blood.V130.Suppl_1.504.504

Published: 2017

Journal Articles

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer Brudno, MD, Norris Lam, BS, Michael Wang, MD, David Stroncek, MD, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Steven Hartman, Jennifer A. Kanakry, MD, Steven Z. Pavletic, MD, Steven A. Feldman, Judith Lawrence, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 524.

https://doi.org/10.1182/blood.V130.Suppl_1.524.524

Published: 2017

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Jennifer N. Brudno, MD, Victoria Shi, David Stroncek, MD, Stefania Pittaluga, MD PhD, Jennifer A. Kanakry, MD, Lauren M. Curtis, MD, Juan C. Gea-Banacloche, MD, Steven Pavletic, MD, Mohammad-Hadi Bagheri, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2016) 128 (22): 999.

https://doi.org/10.1182/blood.V128.22.999.999

Published: 2016

Journal Articles

Chimeric Antigen Receptors/Genetically Modified T-Cells

James N. Kochenderfer, MD

Blood (2016) 128 (22): SCI-37.

https://doi.org/10.1182/blood.V128.22.SCI-37.SCI-37

Published: 2016

Journal Articles

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Arianne Perez, PhD, Lynn Navale, MS, John M. Rossi, MS, Yueh-wei Shen, MS, Yizhou Jiang, PhD, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, Margo R. Roberts, PhD, David D. Chang, MD PhD, James N. Kochenderfer, MD, Adrian Bot, MD PhD

Blood (2015) 126 (23): 2042.

https://doi.org/10.1182/blood.V126.23.2042.2042

Published: 2015

Journal Articles

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Yueh-wei Shen, MS, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, David D. Chang, MD PhD, James N. Kochenderfer, MD, Margo R. Roberts, PhD

Blood (2015) 126 (23): 4426.

https://doi.org/10.1182/blood.V126.23.4426.4426

Published: 2015

Journal Articles

Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor

Syed Abbas Ali, MD, Victoria Shi, Michael Wang, MD, David Stroncek, MD, Irina Maric, Jennifer N Brudno, MD, Maryalice Stetler-Stevenson, Jeremy J. Rose, BA, Steven Feldman, Brenna Hansen, Frances T. Hakim, PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2015) 126 (23): LBA-1.

https://doi.org/10.1182/blood.V126.23.LBA-1.LBA-1

Published: 2015

Journal Articles

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Terry J. Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 684.

https://doi.org/10.1182/blood.V126.23.684.684

Published: 2015

Journal Articles

Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease

Blood (2015) 126 (23): 99.

https://doi.org/10.1182/blood.V126.23.99.99

Published: 2015

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma

James N Kochenderfer, MD, Robert Somerville, PhD, Lily Lu, PhD, Alex Iwamoto, B.S., James C Yang, MD, Christopher Klebanoff, MD, Udai Kammula, MD, Richard M Sherry, MD, Shi Victoria, M.S., Constance Yuan, MD PhD, Steven Feldman, PhD, Tatyana Feldman, MD, Andre Goy, MD MS, Kathleen E Morton, RN, Mary Ann Toomey, RN, Steven A. Rosenberg, MD PhD

Blood (2014) 124 (21): 550.

https://doi.org/10.1182/blood.V124.21.550.550

Published: 2014

Journal Articles

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Blood (2014) 124 (21): 1147.

https://doi.org/10.1182/blood.V124.21.1147.1147

Published: 2014

NARROW

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Infectious Complications Associated with CAR T-Cell Therapy

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Chimeric Antigen Receptors/Genetically Modified T-Cells

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only